Mirati Therapeutics, Inc.
MRTX
Rank in Stocks
#4928
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Share Price
$58.70
Last synced: 2024-01-23
Market Cap
$2.98B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Mirati Therapeutics, Inc. (MRTX)
Category
Healthcare
Stock price history for Mirati Therapeutics, Inc. (MRTX)
Highest end of day price: $58.94 on 2024-01-01
Lowest end of day price: $8.67 on 2013-07-01
Lowest end of day price: $8.67 on 2013-07-01
Stock price history of Mirati Therapeutics, Inc. from 2013 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2024 | 2.02% |
| 2023 | 12.06% |
| 2022 | -63.56% |
| 2021 | -39.15% |
| 2020 | 103.16% |
| 2019 | 189.49% |
| 2018 | 132.29% |
| 2017 | 218.41% |
| 2016 | -84.08% |
| 2015 | 98.82% |
| 2014 | 1.02% |
| 2013 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $520.46 | 22.10% |
US
|
|
| $249.25 | 806.69% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $886.23 | 6.17% |
NL
|
|
| $752.87 | 7.40% |
CH
|
